SAN DIEGO , June 26, 2023 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced it is set to join both the broad-market Russell 3000 ® and small-cap